Beyond Serous: Treatment Options for Rare Endometrial Cancers

Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601.

CAS  PubMed  Article  Google Scholar 

Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293–7.

CAS  PubMed  Article  Google Scholar 

Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

Article  Google Scholar 

Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137(3):581–8.

PubMed  Article  Google Scholar 

Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, et al. Uterine carcinosarcomas: from pathology to practice. Gynecol Oncol. 2021;162(1):235–41.

CAS  PubMed  Article  Google Scholar 

Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31(3):411–23.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Crane E, Naumann W, Tait D, Higgins R, Herzog T, Brown J. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities. Int J Gynecol Cancer. 2020;30(4):480–4.

PubMed  Article  Google Scholar 

Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006;30(12):1519–30.

PubMed  Article  Google Scholar 

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S, Program NCS, et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017;123(17):3261–8.

PubMed  Article  Google Scholar 

Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019;19(9):510–21.

CAS  PubMed  PubMed Central  Article  Google Scholar 

AlHilli M, Elson P, Rybicki L, Amarnath S, Yang B, Michener CM, et al. Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. Int J Gynecol Cancer. 2019;29(7):1126–33.

PubMed  Article  Google Scholar 

Tung HJ, Wu RC, Lin CY, Lai CH. Rare subtype of endometrial cancer: undifferentiated/dedifferentiated endometrial carcinoma, from genetic aspects to clinical practice. Int J Mol Sci. 2022;23(7).

Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih IM. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol. 2014;38(5):660–5.

PubMed  Article  Google Scholar 

Pors J, Segura S, Chiu DS, Almadani N, Ren H, Fix DJ, et al. Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study. Am J Surg Pathol. 2021;45(4):498–506.

PubMed  PubMed Central  Article  Google Scholar 

Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers (Basel). 2021;13(11).

Schlechtweg K, Chen L, St Clair CM, Tergas AI, Khoury-Collado F, Hou JY, et al. Neuroendocrine carcinoma of the endometrium: disease course, treatment, and outcomes. Gynecol Oncol. 2019;155(2):254–61.

PubMed  Article  Google Scholar 

Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol. 2006;101(1):120–5.

PubMed  Article  Google Scholar 

Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331–6.

PubMed  PubMed Central  Article  Google Scholar 

Fader AN, Seamon LG, Escobar PF, Frasure HE, Havrilesky LA, Zanotti KM, et al. Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. Gynecol Oncol. 2012;126(2):180–5.

PubMed  Article  Google Scholar 

Perrone E, Capasso I, Pasciuto T, Gioe A, Gueli Alletti S, Restaino S, et al. Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study. J Gynecol Oncol. 2021;32(3):e45.

Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, et al. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese gynecologic oncology group. Gynecol Oncol. 2016;141(3):447–53.

PubMed  Article  Google Scholar 

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005;99(3):689–95.

PubMed  Article  Google Scholar 

Huang AB, Wu J, Chen L, Albright BB, Previs RA, Moss HA, et al. Neoadjuvant chemotherapy for advanced stage endometrial cancer: a systematic review. Gynecol Oncol Rep. 2021;38:100887.

PubMed  PubMed Central  Article  Google Scholar 

Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, et al. Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemother Pharmacol. 2019;84(2):281–5.

PubMed  Article  Google Scholar 

Schlappe BA, Weaver AL, McGree ME, Ducie J, Zahl Eriksson AG, Dowdy SC, et al. Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol. 2020;156(1):62–9.

PubMed  Article  Google Scholar 

Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg. 2021;156(2):157–64.

PubMed  Article  Google Scholar 

Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021;225(4):367 e1- e39.

Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012;127(1):22–6.

PubMed  Article  Google Scholar 

Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199(5):536 e1-8.

Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017;145(1):78–87.

PubMed  PubMed Central  Article  Google Scholar 

Hamilton SN, Tinker AV, Kwon J, Lim P, Kong I, Sihra S, et al. Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. J Gynecol Oncol. 2022;33(3):e25.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Vandenput I, Trovik J, Vergote I, Moerman P, Leunen K, Berteloot P, et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer. 2011;21(2):332–6.

PubMed  Article  Google Scholar 

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Clear cell carcinoma of the endometrium. Gynecol Oncol. 2022;164(3):658–66.

CAS  PubMed  Article  Google Scholar 

Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, et al. Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG Oncology Trial. J Clin Oncol. 2022;40(9):968–77.

CAS  PubMed  Article  Google Scholar 

Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9.

CAS  PubMed  Article  Google Scholar 

Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol. 2012;124(1):26–30.

CAS  PubMed  Article  Google Scholar 

Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, et al. Bevacizumab in advanced endometrial cancer. Gynecol Oncol. 2021;161(3):720–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928–35.

PubMed  PubMed Central  Article  Google Scholar 

Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, et al. SYD985, a Novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression. Clin Cancer Res. 2017;23(19):5836–45.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.

CAS  PubMed  Article  Google Scholar 

Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, et al. Tumor mutational burden guides therapy in a treatment refractory POLE-mutant uterine carcinosarcoma. Oncologist. 2018;23(5):518–23.

CAS 

留言 (0)

沒有登入
gif